Apellis Pharmaceuticals, Inc. (APLS) reported Q3 EPS of ($1.75), $0.31 worse than the analyst estimate of ($1.44). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $21.74 million.
Apellis Pharmaceuticals, Inc. (APLS) reported Q3 EPS of ($1.75), $0.31 worse than the analyst estimate of ($1.44). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $21.74 million.